Xenetic Biosciences (Xenetic Biosciences) YoY EPS Growth : -39.29% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Xenetic Biosciences's YoY EPS Growth for the quarter that ended in Mar. 2024 was -39.29%.

Xenetic Biosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.78.

Xenetic Biosciences YoY EPS Growth Historical Data

The historical data trend for Xenetic Biosciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences YoY EPS Growth Chart

Xenetic Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

Get a 7-Day Free Trial

34.47

73.14

67.65

16.18

41.21

Xenetic Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EPS Growth	Get a 7-Day Free Trial															53.33	63.68	-23.21	20.62	-39.29

Xenetic Biosciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Xenetic Biosciences's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(-2.71	-	-4.61)	/	\| -4.61 \|
=	41.21 %

Xenetic Biosciences's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EPS Growth (Q: Mar. 2024 )
=	(Earnings per Share (Diluted) (Q: Mar. 2024 )	-	Earnings per Share (Diluted) (Q: Mar. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Mar. 2023 )) \|
=	(-0.78	-	-0.56)	/	\| -0.56 \|
=	-39.29 %

Xenetic Biosciences YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Executives

Grigory G. Borisenko	director	40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov	director	C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow	officer: Chief Financial Officer	C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks	director	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev	director	99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc	10 percent owner	25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110